Hot and cold tumors: Immunological features and the therapeutic strategies DOI Creative Commons
Lianjie Wang, Hui Geng, Yujie Liu

и другие.

MedComm, Год журнала: 2023, Номер 4(5)

Опубликована: Авг. 26, 2023

Abstract The “hotness” or “coldness” of the tumors are determined by information cancer cells themselves, tumor immune characteristics, microenvironment, and signaling mechanisms, which key factors affecting patients’ clinical efficacy. switch mechanism its corresponding pathological characteristics treatment strategies frontier hot spot treatment. How to distinguish effectively clarify causes, microenvironment state, very important for response efficacy treatments. Starting from concept cold tumor, this review systematically summarized molecular influencing factors, therapeutic “hot tumors,” analyzed immunophenotypes, pathways, markers that contribute tumors” in details. Different “cold based on were with drug targets proteins tumors.” Furthermore, combines different traditional medicine modern medicine, provide a basis guidance decision‐making

Язык: Английский

B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma DOI Creative Commons
Ayana T. Ruffin, Anthony R. Cillo, Tracy Tabib

и другие.

Nature Communications, Год журнала: 2021, Номер 12(1)

Опубликована: Июнь 7, 2021

Abstract Current immunotherapy paradigms aim to reinvigorate CD8 + T cells, but the contribution of humoral immunity antitumor remains understudied. Here, we demonstrate that in head and neck squamous cell carcinoma (HNSCC) caused by human papillomavirus infection (HPV ), patients have transcriptional signatures germinal center (GC) tumor infiltrating B cells (TIL-Bs) spatial organization immune consistent with tertiary lymphoid structures (TLS) GCs, both which correlate favorable outcome. GC TIL-Bs HPV HNSCC are characterized distinct waves gene expression dark zone, light zone a transitional state cells. Semaphorin 4a is enhanced on present TLS during differentiation TIL-Bs. Our study suggests therapeutics enhance TIL-B responses should be prioritized future studies determine if they can complement current mediated immunotherapies.

Язык: Английский

Процитировано

240

Host tissue determinants of tumour immunity DOI
Hélène Salmon,

Romain Remark,

Sacha Gnjatic

и другие.

Nature reviews. Cancer, Год журнала: 2019, Номер unknown

Опубликована: Март 12, 2019

Язык: Английский

Процитировано

227

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies DOI Creative Commons
Julie Giraud, Domitille Chalopin, Jean‐Frédéric Blanc

и другие.

Frontiers in Immunology, Год журнала: 2021, Номер 12

Опубликована: Март 18, 2021

Hepatocellular carcinoma (HCC) is the most common liver tumor and among deadliest cancers worldwide. Advanced HCC overall survival meager has not improved over last decade despite approval of several tyrosine kinase inhibitors (TKi) for first second-line treatments. The recent immune checkpoint (ICI) revolutionized palliative care. Unfortunately, majority patients fail to respond these therapies. Here, we elaborate on landscapes normal cirrhotic livers unique microenvironment. We describe molecular immunological classifications HCC, discuss role specific cell subsets in this cancer, with a focus myeloid cells pathways anti-tumor immunity, promotion evasion. also challenges opportunities immunotherapies new avenues based harnessing activity myeloid, NK γδ T cells, vaccines, chimeric antigen receptors (CAR)-T or -NK oncolytic viruses, combination

Язык: Английский

Процитировано

173

Tertiary lymphoid structures in cancer – considerations for patient prognosis DOI Open Access
Luis Munoz‐Erazo,

Janet L Rhodes,

Valentine Marion

и другие.

Cellular and Molecular Immunology, Год журнала: 2020, Номер 17(6), С. 570 - 575

Опубликована: Май 15, 2020

Язык: Английский

Процитировано

168

Role of B cells as antigen presenting cells DOI Creative Commons
Ichwaku Rastogi,

Donghwan Jeon,

Jena E. Moseman

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Сен. 8, 2022

B cells have been long studied for their role and function in the humoral immune system. Apart from generating antibodies an antibody-mediated memory response against pathogens, are also capable of cell-mediated immunity. It has demonstrated by several groups that can activate antigen-specific CD4 CD8 T cells, regulatory cytotoxic effects. The as professional antigen presenting (APCs) to largely understudied. This, however, requires attention recent reports importance within tumor microenvironment, increasingly being evaluated cellular therapies. Antigen presentation through be (B cell receptor (BCR) dependent) or non-specific (BCR independent) mechanisms modulated a variety intrinsic external factors. This review will discuss pathways which present antigens, how differ other APCs.

Язык: Английский

Процитировано

163

B cells and cancer: To B or not to B? DOI Creative Commons
Wolf H. Fridman, Florent Petitprez, Maxime Meylan

и другие.

The Journal of Experimental Medicine, Год журнала: 2020, Номер 218(1)

Опубликована: Дек. 18, 2020

Whereas T cells have been considered the major immune of tumor microenvironment able to induce regression and control cancer clinical outcome, a burst recent publications pointed fact that B may also play prominent role. Activated in germinal centers tertiary lymphoid structures, can directly present tumor-associated antigens or produce antibodies increase antigen presentation kill cells, resulting beneficial impact. Immune complexes inflammation, angiogenesis, immunosuppression via macrophage complement activation, deleterious

Язык: Английский

Процитировано

158

The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications DOI Open Access
Jiajie Hou, Haiyan Zhang, Beicheng Sun

и другие.

Journal of Hepatology, Год журнала: 2019, Номер 72(1), С. 167 - 182

Опубликована: Авг. 23, 2019

Язык: Английский

Процитировано

154

Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma DOI
Guangyu Ding, Jiaqiang Ma, Jing‐Ping Yun

и другие.

Journal of Hepatology, Год журнала: 2021, Номер 76(3), С. 608 - 618

Опубликована: Ноя. 15, 2021

Язык: Английский

Процитировано

144

The roles of tertiary lymphoid structures in chronic diseases DOI Open Access
Yuki Sato, Karīna Siliņa, Maries van den Broek

и другие.

Nature Reviews Nephrology, Год журнала: 2023, Номер 19(8), С. 525 - 537

Опубликована: Апрель 12, 2023

Язык: Английский

Процитировано

129

Tertiary lymphoid structures and B cells: An intratumoral immunity cycle DOI Creative Commons
Wolf H. Fridman, Maxime Meylan, Guilhem Pupier

и другие.

Immunity, Год журнала: 2023, Номер 56(10), С. 2254 - 2269

Опубликована: Сен. 11, 2023

Язык: Английский

Процитировано

116